Chen Jin, Yin Rong, Liu Xinyin
Nanjing Medical University, Nanjing 211166, China.
Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210009, China.
Zhongguo Fei Ai Za Zhi. 2020 Apr 20;23(4):294-298. doi: 10.3779/j.issn.1009-3419.2020.101.05. Epub 2020 Apr 1.
Nowadays, accumulating evidence indicates that long non-coding RNA (lncRNA) play vital roles in tumorigenesis. As a newly discovered lncRNA, FEZ family zinc finger 1-antisense RNA 1 (FEZF1-AS1) is markedly upregulated in various malignant tumors including non-small cell lung cancer (NSCLC). Aberrant expression of FEZF1-AS1 is related to clinical characteristics of patients with NSCLC and suggests poor prognosis. Moreover, FEZF1-AS1 can regulate numerous biological processes, such as cell proliferation, migration and invasion through different mechanisms. In this article, we systematically summarize the recent research progress of FEZF1-AS1 in NSCLC, which might be a novel target for clinical therapy.
如今,越来越多的证据表明长链非编码RNA(lncRNA)在肿瘤发生过程中发挥着至关重要的作用。作为一种新发现的lncRNA,FEZ家族锌指1反义RNA 1(FEZF1-AS1)在包括非小细胞肺癌(NSCLC)在内的多种恶性肿瘤中显著上调。FEZF1-AS1的异常表达与NSCLC患者的临床特征相关,并提示预后不良。此外,FEZF1-AS1可通过不同机制调节细胞增殖、迁移和侵袭等多种生物学过程。在本文中,我们系统地总结了FEZF1-AS1在NSCLC中的最新研究进展,其可能成为临床治疗的新靶点。